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Abstract Cardiovascular disease is a common compli-
cation of diabetes and the leading cause of death among
people with diabetes. Because of the huge premature
morbidity and mortality associated with diabetes, preven-
tion of vascular complications is a key issue. Although the
exact mechanism by which vascular damage occurs in
diabetes in not fully understood, numerous studies support
the hypothesis of a causal relationship of non-enzymatic
glycation with vascular complications. In this review, data
which point to an important role of Amadori-modiﬁed
glycated proteins and advanced glycation endproducts in
vascular disease are surveyed. Because of the potential role
of early- and advanced non-enzymatic glycation in vascu-
lar complications, we also described recent developments
of pharmacological inhibitors that inhibit the formation of
these glycated products or the biological consequences of
glycation and thereby retard the development of vascular
complications in diabetes.
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Introduction
Cardiovascular disease is a common complication of dia-
betes and the leading cause of death among people with
diabetes (Zimmet et al. 2001). Vascular complications in
diabetes can be caused by micro- and macroangiopathy
(Schalkwijk and Stehouwer 2005). Retinal and renal
microangiopathy cause retinopathy and nephropathy, and
microangiopathy of the vasa nervorum contributes to dia-
betic neuropathy. Macroangiopathy in diabetes consists
mainly of an accelerated form of atherosclerosis and affects
all clinically important sites, i.e. the coronary, the carotid
and the peripheral arteries, thus increasing the risk of
myocardial infarction, stroke and peripheral artery disease.
Dysfunction of the vascular endothelium is regarded not
only as an important factor in the initiation of vascular
complications but also in its progression and clinical
sequelae (Cines et al. 1998). The results of large studies in
type 1 and type 2 diabetes provide strong evidence that
hyperglycaemia plays an important role in the pathogenesis
of nephropathy, retinopathy, neuropathy and accelerated
atherosclerosis (The Diabetes Control Complications Trial
Research Group 1993; The Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interventions and
Complications Research Group 2000; UK Prospective
Diabetes Study (UKPDS) Group 1995, 1998). These
studies also emphasised that hyperglycaemia is an inde-
pendent risk factor for these vascular complications
although the exact relationship between glucose control
and macrovascular complications, especially in type 2
diabetes, is still a matter of debate (Skyler et al. 2009).
A growing body of evidence suggests that many hyper-
glycaemia-induced changes that explain the pathogenesis of
vascular complications are mediated by early glycated
proteins and/or advanced glycation endproducts (AGEs)
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DOI 10.1007/s00726-010-0779-9(Goh and Cooper 2008; Genuth et al. 2005) (Fig. 1). Non-
enzymatic glycation involves the condensation reaction of
the carbonyl group of sugar aldehydes with the N-terminus
or free-amino groups of proteins via a nucleophilic addition,
resulting ﬁrst in the rapid formation of a Schiff base.
Through acid–base catalysis, these labile adducts then
undergo rearrangements to the more stable Amadori-
products. Only a small part of these relatively stable
Amadori-products undergo further irreversible chemical
reactions leading to the formation of AGEs. An important
distinction of AGEs, compared with their Amadori-products,
is their irreversible nature. In the complex pathways lead-
ing to the formation of AGEs, it seems that oxidative
stress plays an important role, and therefore, AGEs will
also accumulate under conditions of oxidative stress and
inﬂammation (Baynes and Thorpe 2000).
Because of the potential role of early- and advanced
non-enzymatic glycation in vascular complications, the
development of pharmacological inhibitors that inhibit the
formation of these glycated products or the biological
consequences of glycation and thereby retard the devel-
opment of vascular complications in diabetes is of partic-
ular interest. In this review, data which point to an
important role of Amadori-glycated proteins and AGEs in
the development of vascular complications and recent
developments in therapeutic interventions in the glycation
pathway will be described.
Amadori-glycated proteins and vascular complications
The majority of the glycated proteins in plasma exist as
Amadori-glycated proteins rather than as AGEs. On the
basis of proteomic proﬁling, it was found that glucose
attaches at many different sites in human serum albumin in
vivo as evidenced by the 31 glycation sites (Zhang et al.
2008). In addition to albumin, other high-abundance
plasma proteins were identiﬁed glycated including sero-
transferrin, alpha-1-antitrypsin, alpha-2-macroglobulin,
apolipoprotein A-I and A-II, ﬁbrinogen and alpha-1-acid
glycoprotein as well as several moderately abundant gly-
cated proteins (Jaleel et al. 2005; Dolhofer and Wieland
1980). Although several studies have demonstrated that the
amount of Amadori-modiﬁed proteins is increased in dia-
betic patients, only limited data are available on the asso-
ciation of the plasma concentrations of Amadori-albumin
with the presence and severity of diabetic complications.
In a rodent model of type 2 diabetes, plasma Amadori-
albumin concentrations were elevated twofold and declined
after administration of a monoclonal anti-Amadori albu-
min, and this decrease was accompanied by a decrease of
ﬁbronectin (Cohen et al. 1994) indicating for the ﬁrst time
in vivo that Amadori-albumin contributes causally to dia-
betic vasculopathy. Indeed, infusion of Amadori-albumin
in animal model induced a generalised diabetic vasculop-
athy (Cohen et al. 1996). In support, in type 1 diabetic
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Fig. 1 Formation of Amadori-glycated proteins and advanced glycation endproducts (AGEs) and their putative role in vascular complications
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123patients, Amadori-albumin correlated with the generally
recognised plasma markers of endothelial or vascular
dysfunction (Schalkwijk et al. 1999).
Amadori-albumin exhibits potential deleterious effects
in various vascular cells types, which can be associated
with vascular complications. Amadori-albumin has been
shown to affect the biology of endothelial cells, such as
TNF-a and E-selectin expression, and modulation of nitric
oxide (NO) synthase activity (Amore et al. 1997; Higai
et al. 2006). In human glomerular endothelial cells, Ama-
dori-albumin caused an increase in type IV collagen,
ﬁbronectin and transforming growth factor-b1 (TGF-b1)
expression, with an essential role of PKC signalling and
TGF-b1 activation in collagen production (Chen et al.
2003). Amadori-albumin also affects cell growth in glo-
merular mesangial cells and stimulated production of
ﬁbronectin, TGF-b1, the TGF-b type II receptor and type
IV collagen with the protein kinase C (PKC)-b1 isoform
linked to the stimulation of type IV collagen production
(Cohen et al. 2007; Ziyadeh 2004). In smooth muscle cells,
Amadori-albumin increased the expression of monocyte
chemoattractant protein-1 (MCP-1), increased the activa-
tion of PKC and induced cell proliferation (Hattori et al.
2002). Amadori-albumin-induced production of reactive
oxygen species and activation of tyrosine kinase seemed to
be involved in MCP-1 expression, while activation of
mitogen-activated protein kinases (MAPK) by PKC acti-
vation seemed to be involved in cell proliferation.
Of note, the binding proteins for Amadori-glycated
albumin reported so far in different cell types do not show
any homology with various AGE receptors. In agreement,
Amadori-albumin did not compete with AGE-albumin for
binding to the receptor for AGE (RAGE) (Schmidt et al.
1999).
In accordance with the in vitro ﬁndings indicating a role
of Amadori-glycated albumin in the pathology of vascular
disease, the twofold increased concentration of Amadori-
albumin in type 1 diabetic patients was further increased in
patients with early nephropathy (Schalkwijk et al. 1999).
Afteradjustmentforage,sex,durationofdiabetesandserum
creatinine, Amadori-albumin concentrations remained
independently associated with nephropathy, indicating a
direct pathogenic role for early glycation products in
nephropathy. In addition, Amadori-albumin has been dem-
onstratedinglomeruliofpatientswithdiabeticnephropathy,
and the degree of staining was increased with the severity of
tissue damage (Sakai et al. 1996). These ﬁndings are con-
sistent with a role of Amadori-albumin in the development
of nephropathy. The ﬁrst piece of evidence in this direction
came from the demonstration that intravenous infusion of
Amadori-albumin in animal models induced glomerular
vasodilatation and hyperﬁltration (Sabbatini et al. 1992)
and resulted in renal glomerular changes such as diffuse
thickening of the glomerular basement membrane (GBM).
In agreement, treatment of db/db mice with a monoclonal
anti-Amadori albumin signiﬁcantly reduced urinary protein
excretion, renal type IV collagen and ﬁbronectin mRNA
levels and prevented the fourfold increase in volume of the
mesangial matrix fraction (Cohen et al. 1994). This was
conﬁrmed in diabetic db/db mice treated with a low-
molecular-weight compound that impedes the condensation
of free glucose with lysine e-amino groups in albumin
(Cohen et al. 2000). Thus, Amadori-albumin has been
implicated in the development of diabetic nephropathy.
Amadori-products have also been associated with dia-
betic retinopathy. The initial Amadori product of glycation
on collagen is increased about threefold in type 1 diabetic
patients and is further increased with the presence and
severity of diabetic retinopathy and remained, after
adjustment for age, sex and duration of diabetes, inde-
pendently associated with retinopathy (McCance et al.
1993). We demonstrated the presence of Amadori-albumin
in the retinal capillaries of diabetic patients with retinop-
athy (Schalkwijk et al. 1999). In diabetic db/db mice, the
basement membrane thickening in the capillaries of the
outer plexiform layer of retina from were ameliorated
by treatment with A717 monoclonal antibody Amadori-
albumin (Clements et al. 1998), indicating that Amadori-
glycated albumin is directly involved in the pathogenesis of
diabetic retinopathy.
Amadori-albumin may thus contribute to the pathogen-
esis of diabetic vascular disease. Prospective studies, how-
ever, are needed to determine whether increased plasma
levels of Amadori-albumin in diabetic patients precede the
development of diabetic complications. In addition, further
studies are needed to unravel the intracellular signalling
pathways which are involved in the biological action of
Amadori-albumin. Agents that neutralise or prevent the
formation of an excess of Amadori-glycated proteins in
diabetes may offer a new therapy against early changes
leading to diabetic vascular complications.
AGEs and vascular complications
Although Amadori-products are the major glycated modi-
ﬁcations, so far most studies in vitro and in vivo have
focused on the role of AGEs in diabetic complications.
Biological effects of advanced glycation endproducts
The accumulation of several AGEs in tissue proteins has
been implicated in diabetic vascular complications, such as
retinopathy, nephropathy and neuropathy, in atherosclero-
sis and age-related diseases such as in inﬂammation. At
least three mechanisms have been proposed by which
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development of these complications: (1) the accumulation
of AGEs in the extracellular matrix causing aberrant cross-
linking, resulting in a decrease in the elasticity of vessels,
(2) the binding of circulating AGEs to cellular receptors
and activation of cell signalling pathways with subsequent
modulation of gene expression and (3) intracellular gly-
cation of proteins which may lead to impaired cell
function.
Accumulation of AGEs in the extracellular matrix
Because of their slow turnover rate, structural compo-
nents of the extracellular matrix are highly susceptible
for glycation. Modest hyperglycaemia can even result in
signiﬁcant accumulation of AGEs on long-lived macro-
molecules (Vlassara et al. 1992). A common conse-
quence of AGE accumulation on extracellular matrix
proteins is the formation of cross-links. Complications of
cross-link formation include decreased elasticity and
increased stiffness of vessels, increased thickness and
rigidity, narrowing of the vessel lumen (McNulty et al.
2007), development of sclerosis of renal glomeruli and
atherosclerosis. Several studies have suggested that AGE
cross-linking plays a role in increasing myocardial and
vascular stiffness (Kass et al. 2001; Wolffenbuttel et al.
1998). A recent study found pentosidine levels to be
associated with increased arterial stiffness and thickness
(Yoshida et al. 2005) while another study suggested that
an increase in the concentration of cross-link AGEs
contributes to the stiffening of the aorta (Sims et al.
1996).
The AGE formation on extracellular matrix also inter-
feres with matrix–cell interactions and disturbs biological
attachment sites, which cause changes in signalling
between the matrix and cells and disables cells to adhere to
their substrates. AGE-induced changes in adhesion and
spreading may be an important initial event in the patho-
genesis of diabetic microangiopathy that contributes to
cellular dysfunction and a disturbed functioning of blood
vessels. For example, AGE modiﬁcation of type IV colla-
gen’s binding cell-binding domain decreases endothelial
cell adhesion (Haitoglou et al. 1992). Other long-lived
proteins such as tubulin, myelin and lens crystallins are
also target for glycation. AGE modiﬁcation of lens crys-
tallins contributes to cataract formation during ageing and
diabetes. In addition, the composition of the extracellular
matrix can be modiﬁed by AGEs by AGE-induced
expression of extracellular matrix proteins (Throckmorton
et al. 1995). Thus, the presence of AGEs on long-lived
proteins may have deleterious pathological consequences
by different mechanisms.
Intracellular glycation of proteins
Among all naturally occurring sugars, glucose has the
slowest glycation rate. It has been shown that glucose-
derived glycolytic intermediates or intracellular sugars
form much more glycated proteins and at a faster rate than
do equimolar amounts of glucose. The glucose-derived
glycolytic intermediate glucose-6-phosphate, the triose
phosphates glyceraldehydes-3-phosphate and dihydroxy-
acetonphosphate and the dicarbonyl compounds glyoxal
(GO), methylglyoxal (MGO) and 3-deoxyglucosone (3-DG)
play an important role in the fast intracellular Maillard
reaction (Thornalley 2005a). Therefore, intracellular AGE
formation has gained an important role in the link between
AGEs and diabetic complications. Indeed, it has been
shown that intracellular AGEs are implicated in activating
intracellular signalling pathways as well as in modifying
the function of intracellular proteins, thereby contributing
to diabetic vascular complications (Brownlee 2005).
The highly reactive dicarbonyl compound MGO has
been identiﬁed as the major precursor in the formation of
intracellular AGEs in endothelial cells (Shinohara et al.
1998; Miyata et al. 2001). In endothelial cells, basic
ﬁbroblast growth factor (bFGF) undergoes increased non-
enzymatic glycation when exposed to hyperglycaemia
resulting in an altered vascular function, including a
reduced mitogenic activity of the endothelial cell (Giardino
et al. 1994). Intracellular AGE formation also reduces the
expression of endothelial NO synthase (eNOS) through
increased eNOS mRNA degradation. In addition, studies
have shown that AGEs quench NO and thereby directly
lead to inactivation of NO. Reduced eNOS activity and
inactivation of NO by AGEs may play an important role in
the defective vasodilatory responses that occur in diabetes
(Soro-Paavonen et al. 2010). AGEs also block the anti-
proliferative effects of NO on vascular smooth muscles
cells, which subsequently contributes to atherosclerosis. It
has been demonstrated that hyperglycaemia also alters
mitochondrial function through glycation of mitochondrial
proteins. MGO-induced modiﬁcations of speciﬁc mito-
chondrial proteins were detected in kidney of diabetic rats,
which were paralleled by increases in superoxide formation
by mitochondria (Rosca et al. 2005). In addition, antioxi-
dant enzymes such as glutathione reductase and glutathione
peroxidase are also modiﬁed by MGO, contributing to
increased oxidative stress (Wu and Juurlink 2002). Other
important enzymes, such as GAPDH, are modiﬁed by
MGO, which in turn lead to inhibition of the enzyme
activity (Lee et al. 2005). MGO also causes posttransla-
tional modiﬁcations of regulatory proteins, thereby pro-
viding a mechanism for regulation of gene expression and
modifying cellular functions (Yao et al. 2007). Recently, it
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123has been shown that MGO modiﬁes major proteasome
proteins, resulting in impaired proteasome function (Que-
isser et al. 2010). We recently demonstrated in glyoxalase 1
overexpression rats that hyperglycaemia-induced impair-
ment of endothelium-dependent vasorelaxation in diabetic
rats is mediated by increased intracellular MGO levels in a
pathway dependent on oxidative stress (Brouwers et al.
2010), underlining the importance of an increase in intra-
cellular AGE formation for diabetic vascular complication.
Binding of AGEs to cellular receptors
The AGEs and AGE precursors such as dicarbonyl com-
pounds can diffuse out of the cells and can modify circu-
lating matrix proteins and proteins in the blood. Binding of
circulating AGEs to different receptors on different cell
types may lead to the activation of these receptors and
subsequently activate key cell signalling pathways or to
removal and break-down of circulating AGEs. A number of
AGE-binding proteins have been identiﬁed, including
macrophage scavenger receptors type I and II, oligo-
saccharyltransferase-48 (AGE-R1), 80K-H phosphoprotein
(AGE-R2), galectin-3, CD36, LOX-170 and RAGE
(Vlassara and Bucala 1996). So far, the functions of AGE-
R1 and RAGE are studied in more detail.
AGE-R1 is a cell surface-associated receptor that
opposes excessive ROS generation by AGEs. AGE-R1 is
linked to the endocytosis and removal of AGEs (Lu et al.
2004) and to the suppression of RAGE, MAPK, and NF-B
activity, apparently via inhibition of AGE-induced ROS
generation (Cai et al. 2008). Thus, AGE-R1 appears to
control the activation of distinct cellular pathways and
protects against vascular disease promoted by oxidants,
such as via the AGE–RAGE axis (Cai et al. 2010).
RAGE is the best-characterised and the most-studied
receptor for AGEs (Yan et al. 2010). RAGE is a multili-
gand receptor and a member of the immunoglobulin
superfamily of cell surface molecules (Neeper et al. 1992;
Schmidt et al. 1994). Activation of AGE–RAGE-induced
signalling pathways causes modulation of gene expression
of its target genes, which contribute to the development of
vascular disease and diabetic complications. Among these,
target genes are endothelin-1, vascular cell adhesion mol-
ecule-1, intercellular adhesion molecule-1, E-selectin,
vascular endothelial growth factor (VEGF), inﬂammatory
cytokines and growth factors (Goldin et al. 2006).
The ﬁrst identiﬁed ligands for RAGE were AGEs, but it
soon became evident that a number of other ligands also
interact with RAGE including members of the S100/cal-
granulin family and high-mobility group box-1 (Bierhaus
and Nawroth 2009).The structural diversity of RAGE
ligands and the fact that RAGE recognises a class of
ligands led to the hypothesis that RAGE is a pattern
recognition receptor (Schmidt et al. 2001). RAGE is
expressed in most tissues and is found on the cell surface of
a variety of cells, including endothelial cells, mononuclear
phagocytes, monocytes and macrophages, hepatocytes,
smooth muscle cells, certain neurons, astrocytes, microglia,
mesangial cells and podocytes. Under normal homeostasis,
the expression of RAGE is low, while pathogenic condi-
tions such as inﬂammation and diabetes, and at sites of
accumulated AGEs in the vasculature, a sustained upreg-
ulation of RAGE has been shown.
BindingofAGEstoRAGEinducesactivationofmultiple
cellular signal transduction pathways, including activation
of p21ras pathway and a cascade of MAPK (Schmidt et al.
1995, 1999). Activation of these MAPK results in nuclear
translocation and activation of NF-jB and subsequently to
transcription of the target genes, including adhesion mole-
cules and pro-inﬂammatory cytokines. One important facet
of the AGE–RAGE axis is increased expression of RAGE
itself and NF-jBp65, thereby leading to a continued main-
tenance and ampliﬁcation of the signalling pathways and
inﬂammatory events (Bierhaus et al. 2001). In addition to
activation of MAPK, a cdc42/rac pathway and JAK/STAT
pathway are induced upon ligand engagement (Bierhaus
etal.2005).Thediversityofsignallingcascadesidentiﬁedin
RAGE-mediated cellular signalling implies that different
RAGE ligands might induce different pathways, especially
in different cell types. Although multiple pathways down-
stream of RAGE have been identiﬁed, the proximal signal-
ling proteins which actually bind to the receptor’s cytosolic
tail to initiate the signalling events have not yet been iden-
tiﬁed.OligomerisationofRAGEseemstoplayacriticalrole
in activation of RAGE and the induction of downstream
signalling pathways. It has been shown that RAGE oligo-
merises on plasma membranes of human cells, and that this
oligomerisation provides a mechanism to increase the
number of binding sites and is required for high afﬁnity
binding of ligands (Xie et al. 2008).
The RAGE transgenic and knockout mice have also
provided functional genomic models to identify the roles of
RAGE in several disease states (Soro-Paavonen et al. 2008;
Bierhaus et al. 2004; Wendt et al. 2003). Induction of
diabetes in RAGE-deﬁcient knockout mice conﬁrms that
RAGE contributes, at least partly, to the development of
vascular complications and to the induction of inﬂamma-
tion. RAGE deﬁciency prevented diabetes-induced
increases in renal mitochondrial superoxide production in
hyperglycaemic environments and providing further evi-
dence of a role for the AGE–RAGE pathway in the
development and progression of diabetic vascular disease
(Coughlan et al. 2009). Thus, a substantial number of in
vitro and in vivo studies have demonstrated that activation
of the AGE–RAGE axis plays an important role in vascular
dysfunction and inﬂammation (Hudson et al. 2003).
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As described above, inhibition of Amadori-albumin for-
mation, AGE formation and the AGE–RAGE axis as well
as AGE cross-link breaking are potential targets for the
treatment of diabetic complications (Fig. 2).
Inhibition of Amadori-albumin formation
Amadori-glycated albumin has been implicated in the
development of diabetic nephropathy and retinopathy. This
was conﬁrmed in diabetic animal models treated with a
low-molecular-weight compound (EXO-226) that impedes
the condensation of free glucose with lysine e-amino
groups in albumin (Cohen et al. 2000). Administration of
EXO-226 in diabetic animals normalised the plasma con-
centration of Amadori-albumin and reduced urinary albu-
min excretion and the overexpression of mRNA encoding
for collagen (type IV) in the renal cortex as compared with
their untreated diabetic controls.
GLY-230 (2-[3-chlorophenylamino]phenylacetic acid)
is a new small molecule that inhibits modiﬁcation of
albumin by Amadori glucose adducts. In preclinical studies
in diabetic animal models, GLY-230 signiﬁcantly reduced
Amadori-albumin, decreased urine albumin excretion,
restored glomerular nephrin, downregulated TGF-b1 and
VEGF overexpression, ameliorated matrix accumulation,
histomorphometric changes and the development of renal
insufﬁciency as well as vitreous alterations (Cohen et al.
2002, 2005, 2007, 2008). A recent study in diabetic man
demonstrated that GLY-230 lowers glycated albumin and
that this decrease is associated with a reduction in urine
albumin excretion in patients with pre-existing microal-
buminuria (Kennedy et al. 2010).
On the basis of these data, neutralisation or inhibition of
Amadori-albumin in diabetes may be a potential novel
target for therapy against the development of diabetic
vascular complications and encourage further evaluation of
GLY-230 in diabetic renal dysfunction.
Inhibition of AGE formation
Aminoguanidine (Pimagedine) was the ﬁrst AGE inhibitor
studied (Brownlee et al. 1986). Randomised, placebo-
controlled trials have evaluated aminoguanidine in patients
with type 1 and 2 diabetes. In a phase III clinical trial in
type 1 diabetic patients, aminoguanidine reduced protein-
uria and progression of retinopathy, whereas the progres-
sion to overt nephropathy was not statistically improved
(Bolton et al. 2004). This was the ﬁrst clinical proof of the
concept that inhibiting AGE formation can result in a
clinically important attenuation of the serious complica-
tions of type 1 diabetes mellitus. However, a trial in 599
type 2 diabetic patients was discontinued due to safety
concerns and lack of efﬁcacy of aminoguanidine. Amino-
guanidine is reported to have side effects in patients in the
high-dose arm of the study, which include ﬂu-like symp-
toms, abnormalities in liver function test, gastrointestinal
disturbances, rare vasculitis and anaemia (Freedman et al.
1999). Despite the earlier promising results with amino-
guanidine, it is unlikely to be used for therapeutic purposes.
Pyridoxamine, a vitamin B6 derivative, prevents the
formation of AGEs from Amadori-intermediates (Khalifah
et al. 2005) and cleaves 3-DG-reactive carbonyl interme-
diates (Chetyrkin et al. 2008). It inhibits the progression of
renal disease and decreases hyperlipidemia and apparent
redox imbalances in type 1 diabetic rats (Degenhardt et al.
2002). In phase II studies in patients with diabetic
glucose
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123nephropathy, pyridoxamine signiﬁcantly reduced the
change from baseline in serum creatinine, whereas no dif-
ferences in urinary albumin excretion were seen (Williams
et al. 2007). In relation to derivatives of vitamin B6 such as
pyridoxamine, recent research has indicated that vitamins
B6, B9 and B12 co-therapy in diabetic nephropathy accel-
erates decline in renal function (House et al. 2010). How-
ever, it is unlikely that this effect is due to vitamin B6 and
thereby compromises the use of pyridoxamine (Thornalley
and Rabbani 2010).
Benfotiamine, a pro-drug of thiamine monophosphate,
has AGE-lowering properties without decreasing early
glycation adducts (Karachalias et al. 2010). Benfotiamine
as well as thiamine reduces diabetic nephropathy and ret-
inopathy in experimental animal models (Babaei-Jadidi
et al. 2003; Hammes et al. 2003). It acts by correction of
multiple pathways of biochemical dysfunction, and its
major intervention in AGE formation at pharmacologically
relevant concentrations in vivo is by preventing dicarbonyl
formation (Thornalley 2005b). Administration of benfoti-
amine to type 2 diabetic patients, on a high AGE content
diet, reduced circulating AGE levels and markers of oxi-
dative stress (Stirban et al. 2006). In a pilot study,
Brownlee and coworkers found that treatment with oral
benfotiamine plus a-lipoic acid normalises several com-
plication-causing pathways in patients with type 1 diabetes
(Du et al. 2008). In a pilot study in type 2 diabetic patients
with microalbuminuria, high-dose thiamine therapy pro-
duced a regression of urinary albumin excretion (UAE)
(Rabbani et al. 2009). However, a recent double-blind,
randomised, placebo-controlled clinical trial on benfoti-
amine treatment in type 2 diabetic patients with nephrop-
athy, high-dose benfotiamine treatment for 12 weeks as
add-on to angiotensin converting enzyme inhibitors (ACE-
Is) or angiotensin receptor blockers (ARBs) did not reduce
UAE despite improvement of thiamine status (Alkhalaf
et al. 2010). It might be that thiamine derivatives provide
protective effects in earlier stages of diabetic nephropathy.
Therefore, long-term intervention studies and/or interven-
tion studies in earlier stages of diabetic nephropathy are
necessary to discern whether benfotiamine has the effect on
the development of diabetic nephropathy.
The AGE inhibitors with structural features of amino-
guanidine have been developed, including ALT-946 and
OPB-9195. ALT-946 therapy reduces renal AGE accu-
mulation and cortical tubular degeneration to a greater
extent than aminoguanidine and, unlike aminoguanidine,
reduces albumin excretion rate in the hypertensive trans-
genic (mRen-2)27 rat with streptozotocin-induced diabetes
(Wilkinson-Berka et al. 2002). In another study, ALT-946
reduced equally albuminuria in a diabetic rat model either
at the onset of diabetes or 16 weeks later (Forbes et al.
2001). No human data with this agent have been published.
OPB-9195, a thiazolidine derivative, is an agonist of
the peroxisome proliferator-activated receptor. It inhibits
glycoxidation and lipoxidation, thereby decreasing the
formation of AGEs and dicarbonyl intermediates. OPB-
9195 prevented the progression of diabetic glomerular
sclerosis in OLETF rats mainly by lowering serum levels
of AGEs and attenuating AGE deposition in the glomeruli
(Nakamura et al. 1997), most probably by scavenging
dicarbonyl intermediates (Miyata et al. 1999). In stroke-
prone spontaneously hypertensive rats, OPB-9195 also
slowed the progression of nephropathy, lowered blood
pressure and reduced oxidative stress (Mizutani et al.
2002). This compound unfortunately traps pyridoxal-like
aminoguanidine with an attendant toxicity, which has
prevented its use in humans.
Aromatic compounds with AGE inhibitory effects have
been developed, including LR-90 (Rahbar and Figarola
2003). LR-90 inhibits renal and circulating AGE accumu-
lation through its potent metal chelating ability and its
interaction with reactive carbonyl species (Figarola et al.
2003). Given to experimental models of both type 1 and
type 2 diabetic nephropathy, it affords renoprotection such
as improved albuminuria, glomerulosclerosis and tubulo-
interstitial ﬁbrosis, concomitantly with a reduction of renal
AGEs, TGF-b1, connective tissue growth factor, ﬁbro-
nectin and collagen IV collagen deposition.
In a screening of a large chemical library of ca. 1,300
compounds, edaravone, a drug used to treat cerebral
infarction, was discovered that had in vitro AGE inhibi-
tory activity (Tsujita et al. 2004). Unfortunately, edarav-
one also traps pyridoxal, limiting thus its clinical
usefulness. Taking advantage of edaravone’s structure, a
novel AGE inhibitor, TM2002, was synthesised, that does
not trap pyridoxal (Izuhara et al. 2008). In vitro, TM2002
is a powerful AGE inhibitor. Like ARBs it also inhibits
efﬁciently markers of oxidation, chelates transition metal,
but does not bind to the angiotensin II type 1 receptor. It
is readily bioavailable and non-toxic. In vivo, TM2002
given either acutely or for 8 weeks has no adverse effects.
In four different rat models of renal injury and of car-
diovascular injury, it improves renal and cardiovascular
lesions without modiﬁcation of blood pressure. Interest-
ingly, it also decreased signiﬁcantly infarct volume in
both transient and permanent focal ischaemia rat models
(Takizawa et al. 2007). TM2002 inhibition of advanced
glycation and oxidative stress was conﬁrmed by a sig-
niﬁcant reduction of the number of cells positive for
AGEs and heme oxygenase-1 and by a reduced level of
protein carbonyl formation in parts of the brain. Like
ARBs, but unlike aminoguanidine, OPB-9195, pyridox-
amine and LR-90, TM2002 does not trap carbonyl pre-
cursors and belongs thus to a new class of AGE
inhibitors.
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blockers
Renal protection of ARBs is usually explained exclusively
by their blood pressure lowering action and by the inhibi-
tion of the renin angiotensin system. Recently, however,
other pleiotropic actions of ARBs have been invoked. For
example, we and others (Forbes et al. 2002; Miyata et al.
2002) reported that ARBs and ACEIs blocked the forma-
tion of AGEs through the reduction rather than through the
entrapment of precursor carbonyl compounds. Interest-
ingly, these inhibitory actions are not observed in other
classes of anti-hypertensive agents, such as calcium chan-
nel blockers, diuretics and beta blockers (Izuhara et al.
2005). This ﬁnding ﬁts with clinical experience that
inhibitors of the RAS are better renoprotectors than other
types of anti-hypertensive drugs (Wolf and Ritz 2005). In
this model, the renal beneﬁts of ARB appear independent
of the effects on systemic blood pressure and on metabolic
abnormalities. Of note, the amount of the renal pentosidine
fell only with ARBs and correlated with the inhibition of
proteinuria. The expression of markers of oxidative stress
decreased in parallel with the reduction of AGEs.
In order to dissect the mechanisms of ARBs’ protective
beneﬁts, a novel, non-toxic ARB derivative R-147176 was
synthesised. R-147176 has a very weak afﬁnity for the
angiotensin II type 1 receptor, but a strong inhibition of
oxidative stress and AGE formation (Izuhara et al. 2008).
Despite a minimal effect on blood pressure, this compound
provides a signiﬁcant renoprotection in two different
experimental type 2 diabetic rat models. Renal beneﬁts of
ARBs thus depend, at least partly, on their ability to inhibit
oxidative stress and AGE formation. Of interest, R-147176,
like ARBs, protected not only the kidney but also brain
cells in an experimental rat stroke model (Takizawa et al.
2009).
AGE breakers
One of the consequences of AGE accumulation is
increased cross-linking in cardiovascular tissue with a
resulting increase in vascular stiffness. An increase in
cardiovascular stiffness is known to be an important risk
factor for cardiovascular mobility and mortality. In 1996,
Alteon reported the ﬁrst AGE cross-link breaker phen-
ylthiazolium bromide (Vasan et al. 1996). Although this
compound was not further developed because of the
instability in aqueous solutions (Thornalley and Minhas
1999), studies with this compound provided a proof of
concept that cross-link breakers are potential pharmaco-
logical drugs. Based on the experiences with this com-
pound, the highly potent cross-link breaker ALT-711 was
developed. However, it should be noted that Baynes and
co-workers conﬁrmed instability of phenylthiazolium bro-
mide and also found similar instability for ALT-711 (Price
et al. 2001). ALT-711 (alagebrium) is a small easily syn-
thesised compound (3-phenacyl-4,5-dimethylthiazolium
chloride) and is the ﬁrst drug in a new class of thiazolium
therapeutic agents that break established AGE cross-links
between proteins. ALT-711 is being developed for car-
diovascular diseases including systolic hypertension. ALT-
711 is effective in reducing large artery stiffness, slowing
pulse-wave velocity, enhancing cardiac output, left ven-
tricular mass, cardiac expression of brain natriuretic pep-
tide and improving left ventricular diastolic distensibility
(Asif et al. 2000; Wolffenbuttel et al. 1998; Little et al.
2005). Additionally, in experimental diabetes, ALT-711
treatment attenuated atherosclerosis (Forbes et al. 2004)
and diabetic nephropathy (Thallas-Bonke et al. 2004). The
effect was not only on the reduction of renal AGEs but also
on putative mediators of renal injury, such as prosclerotic
cytokines, protein kinase C and oxidative stress. ALT-711
is the only AGE-cross-link breaker in advanced human
testing.
RAGE antagonist
Studies performed in vitro and in vivo revealed the AGE–
RAGE axis as one of the major accounts in the develop-
ment of diabetic vascular complications. The AGE–RAGE
axis would thus be considered as a candidate molecular
target for overcoming diabetic vascular complications. This
concept is supported by the observation that low-molecu-
lar-weight heparin functions as an antagonist of RAGE and
prevents diabetic nephropathy (Myint et al. 2006).
Thiazolidinediones (TZDs) are ligands of the peroxi-
some proliferator-activated receptor-gamma (PPAR-
gamma); TZDs, such as rosiglitazone (Wang et al. 2006),
have also been recently identiﬁed as RAGE antagonists.
They exert beneﬁcial effects in diabetic nephropathy
independently of insulin sensitisation. Interestingly, rosig-
litazone administered to type 2 diabetic subjects increased
the serum level of protective sRAGEs besides the decrease
of circulating AGE levels (Tan et al. 2007).
Studies with RAGE knockout mice that do not express
sRAGE or full-length RAGE suggest that sRAGE acts via
inhibition of RAGE-dependent phenomena (Bierhaus et al.
2005). Recently, it has been postulated that ACE inhibition
reduces the accumulation of AGE in diabetes partly
through an increased production and secretion of sRAGE
into the plasma (Forbes et al. 2005). It remains to be seen
whether sRAGE acts as an antagonist inhibiting the RAGE-
dependent signalling pathways, or as a binder of various
RAGE ligands such as AGEs. sRAGE or possibly a non-
peptide RAGE antagonist may thus become a future ther-
apeutic target (Goh and Cooper 2008).
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123Conclusion
A growing body of evidence demonstrates a role of non-
enzymatic glycation in the development of diabetic vas-
cular complications including diabetic nephropathy and
retinopathy. Several agents interfering with the glycation
pathway have protected the organs in experimental diabetic
models. Some of these agents, tested in human clinical
studies, open encouraging new therapeutic avenues.
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